Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankroll phase 3 trials of its ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...